Anaptysbio (ANAB) Net Cash Flow (QoQ) (2016 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) Net Cash Flow (QoQ) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Anaptysbio | 1.63 Bn | 1.34 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -92.00% |
| Dec 31, 2025 | 95.87% |
| Sep 30, 2025 | 220.60% |
| Jun 30, 2025 | -122.31% |
| Mar 31, 2025 | 64.32% |
| Dec 31, 2024 | -157.20% |
| Sep 30, 2024 | 560.71% |
| Jun 30, 2024 | 2.23% |
| Mar 31, 2024 | 83.35% |
| Dec 31, 2023 | 208.52% |
| Sep 30, 2023 | 84.99% |
| Jun 30, 2023 | -355.25% |
| Mar 31, 2023 | 82.23% |
| Dec 31, 2022 | 197.01% |
| Sep 30, 2022 | 86.11% |
| Jun 30, 2022 | 71.24% |
| Mar 31, 2022 | -306.67% |
| Dec 31, 2021 | 3,811.17% |
| Sep 30, 2021 | -91.53% |
| Jun 30, 2021 | 42.78% |